Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate

Most gastrointestinal stromal tumors (GISTs) are caused by activating mutations of the KIT receptor tyrosine kinase. The small molecule inhibitor imatinib mesylate was initially developed to target the ABL1 kinase, which is constitutively activated through chromosomal translocation in BCR-ABL1-posit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Rausch, Jessica L., Boichuk, Sergei, Ali, Areej A., Patil, Sneha S., Lee, Donna M., Brown, Matthew F., Makielski, Kathleen R., Liu, Ying, Taguchi, Takahiro, Kuan, Shih-Fan, Duensing, Anette
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354847/
https://ncbi.nlm.nih.gov/pubmed/27965460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13882
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados